Whats more, a recent retrospective, multicenter cohort study denied higher occurrence of nonarteritic anterior ischemic optic neuropathy (NAION) in GLP-1RAs users and suggested that its potential benefits for blood glucose control and cardiovascular health likely outweigh its risks (Chou et al., 2025), despite that a few research have reported association between semaglutide prescription and a higher risk of NAION(61)
It's rumored to be popular among celebrities in Hollywood for weight loss, although few have spoken openly about using it
Although our findings do not rule out the possibility of an increased risk of non-arteritic anterior ischemic optic neuropathy when using semaglutide for obesity, the low number of observed events suggests that any potential risk is likely of limited absolute magnitude, Professor Pottegrd added
Forge Performance Co
You can only make it harder for the criminals to do their job. Shabbir Safdar, quoted in "Revealed: Fake Online Pharmacies Thriving Despite DEA Crackdown," Kate Plummer, Newsweek, February 2025 Summer 2024 "In the best-case scenario, consumers just lose their money
This means the FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they are marketed." (Source: FDA "Compounding and the FDA: Questions and Answers".) Clinical efficacy data such as the 14.9% mean weight loss from the STEP 1 trial or the 22.5% from SURMOUNT-1 comes from studies of the FDA-approved formulations, not from compounded versions
